Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.
06-26-2021 | ADA 2021 | Conference coverage | News
People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.
Long-term dulaglutide use may reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes, particularly those with underlying cardiovascular disease, shows an exploratory analysis of REWIND data.
More on GLP-1 receptor agonists
07-05-2021 | ADA 2021 | Conference coverage | News